Powder: -20°C for 3 years | In solvent: -80°C for 1 year
LSZ-102 is an effective and selective degrader of estrogen receptor (IC50 = 0.2 nM) and can be used in studies about ERα positive breast cancer.
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
1 mg | In stock | $ 98.00 | |
2 mg | In stock | $ 147.00 | |
5 mg | In stock | $ 247.00 | |
10 mg | In stock | $ 413.00 | |
25 mg | In stock | $ 692.00 | |
50 mg | In stock | $ 985.00 | |
1 mL * 10 mM (in DMSO) | In stock | $ 256.00 |
Description | LSZ-102 is an effective and selective degrader of estrogen receptor (IC50 = 0.2 nM) and can be used in studies about ERα positive breast cancer. |
In vitro | LSZ-102 causes significant degradation of ERα after 24 h when given as a 10 μM solution to MCF-7 cells. LSZ-102 currently in Phase I/Ib trials for the treatment of ERα positive breast cancer. Robust inhibition of cell proliferation in MCF-7 cells is observed upon incubation with LSZ-102 with a half inhibitory concentration of 1.7 nM. Results show that LSZ-102 effectively inhibits the estrogen-induced activation of the ERE-luciferase reporter using charcoal-stripped serum treated with E2 (IC50: 0.3 nM)[1]. |
In vivo | In male Sprague-Dawley rats, LSZ-102 (3 mg/kg) causes 33% bioavailability and a dose-normalized exposure of 620 nM•h. In mice, LSZ-102 (20 mg/kg) causes significant tumor growth inhibition resulting in tumor stasis[1]. |
Synonyms | LSZ102 |
Molecular Weight | 470.46 |
Formula | C25H17F3O4S |
CAS No. | 2135600-76-7 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 90 mg/mL (191.3 mM), Sonication is recommended.
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
LSZ-102 2135600-76-7 Endocrinology/Hormones Estrogen Receptor/ERR LSZ 102 LSZ102 inhibitor inhibit